1. Home
  2. STG vs PRLD Comparison

STG vs PRLD Comparison

Compare STG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STG
  • PRLD
  • Stock Information
  • Founded
  • STG 2003
  • PRLD 2016
  • Country
  • STG China
  • PRLD United States
  • Employees
  • STG N/A
  • PRLD N/A
  • Industry
  • STG Other Consumer Services
  • PRLD Medicinal Chemicals and Botanical Products
  • Sector
  • STG Real Estate
  • PRLD Health Care
  • Exchange
  • STG Nasdaq
  • PRLD Nasdaq
  • Market Cap
  • STG N/A
  • PRLD 73.7M
  • IPO Year
  • STG 2018
  • PRLD 2020
  • Fundamental
  • Price
  • STG $5.24
  • PRLD $0.77
  • Analyst Decision
  • STG
  • PRLD Strong Buy
  • Analyst Count
  • STG 0
  • PRLD 2
  • Target Price
  • STG N/A
  • PRLD $4.50
  • AVG Volume (30 Days)
  • STG 4.4K
  • PRLD 254.5K
  • Earning Date
  • STG 03-21-2025
  • PRLD 03-10-2025
  • Dividend Yield
  • STG N/A
  • PRLD N/A
  • EPS Growth
  • STG N/A
  • PRLD N/A
  • EPS
  • STG 3.43
  • PRLD N/A
  • Revenue
  • STG $272,664,301.00
  • PRLD $7,000,000.00
  • Revenue This Year
  • STG N/A
  • PRLD N/A
  • Revenue Next Year
  • STG N/A
  • PRLD N/A
  • P/E Ratio
  • STG $1.59
  • PRLD N/A
  • Revenue Growth
  • STG N/A
  • PRLD N/A
  • 52 Week Low
  • STG $4.25
  • PRLD $0.63
  • 52 Week High
  • STG $11.06
  • PRLD $6.80
  • Technical
  • Relative Strength Index (RSI)
  • STG 43.16
  • PRLD 50.06
  • Support Level
  • STG $5.40
  • PRLD $0.71
  • Resistance Level
  • STG $5.84
  • PRLD $0.76
  • Average True Range (ATR)
  • STG 0.25
  • PRLD 0.07
  • MACD
  • STG 0.01
  • PRLD 0.02
  • Stochastic Oscillator
  • STG 39.94
  • PRLD 58.46

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: